Teclistamab for Relapsed or Refractory Multiple Myeloma: Managing Side Effects and Long-Term Outcomes Teclistamab, marketed as TECVAYLI®, is a B-cell maturation antigen (BCMA) × CD3 bispecific antibody used to treat …
Tag: